MicroRNA based theranostics for brain cancer: basic principles
Abstract Background Because of the complexity of the blood-brain barrier (BBB), brain tumors, especially the most common and aggressive primary malignant tumor type arising from the central nervous system (CNS), glioblastoma, remain an essential challenge regarding diagnostic and treatment. There ar...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-05-01
|
Series: | Journal of Experimental & Clinical Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13046-019-1180-5 |
id |
doaj-104ebdc7f475437984a9e87665c75670 |
---|---|
record_format |
Article |
spelling |
doaj-104ebdc7f475437984a9e87665c756702020-11-25T03:46:31ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662019-05-0138112110.1186/s13046-019-1180-5MicroRNA based theranostics for brain cancer: basic principlesGeorge E. D. Petrescu0Alexandru A. Sabo1Ligia I. Torsin2George A. Calin3Mihnea P. Dragomir4Carol Davila University of Medicine and PharmacyMarie Curie Emergency Clinical Hospital for ChildrenElias Clinical Emergency Hospital, Anaesthesiology and Critical Care DepartmentDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer CenterDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer CenterAbstract Background Because of the complexity of the blood-brain barrier (BBB), brain tumors, especially the most common and aggressive primary malignant tumor type arising from the central nervous system (CNS), glioblastoma, remain an essential challenge regarding diagnostic and treatment. There are no approved circulating diagnostic or prognostic biomarkers, nor novel therapies like immune checkpoint inhibitors for glioblastoma, and chemotherapy brings only minimal survival benefits. The development of molecular biology led to the discovery of new potential diagnostic tools and therapeutic targets, offering the premise to detect patients at earlier stages and overcome the current poor prognosis. Main body One potential diagnostic and therapeutic breakthrough might come from microRNAs (miRNAs). It is well-known that miRNAs play a role in the initiation and development of various types of cancer, including glioblastoma. The review aims to answer the following questions concerning the role of RNA theranostics for brain tumors: (1) which miRNAs are the best candidates to become early diagnostic and prognostic circulating biomarkers?; (2) how to deliver the therapeutic agents in the CNS to overcome the BBB?; (3) which are the best methods to restore/inhibit miRNAs? Conclusions Because of the proven roles played by miRNAs in gliomagenesis and of their capacity to pass from the CNS tissue into the blood or cerebrospinal fluid (CSF), we propose miRNAs as ideal diagnostic and prognostic biomarkers. Moreover, recent advances in direct miRNA restoration (miRNA mimics) and miRNA inhibition therapy (antisense oligonucleotides, antagomirs, locked nucleic acid anti-miRNA, small molecule miRNA inhibitors) make miRNAs perfect candidates for entering clinical trials for glioblastoma treatment.http://link.springer.com/article/10.1186/s13046-019-1180-5microRNAmiRNA based drugsAntagomirsAntisense oligonucleotidesmiRNA masksSmall molecule miRNA inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
George E. D. Petrescu Alexandru A. Sabo Ligia I. Torsin George A. Calin Mihnea P. Dragomir |
spellingShingle |
George E. D. Petrescu Alexandru A. Sabo Ligia I. Torsin George A. Calin Mihnea P. Dragomir MicroRNA based theranostics for brain cancer: basic principles Journal of Experimental & Clinical Cancer Research microRNA miRNA based drugs Antagomirs Antisense oligonucleotides miRNA masks Small molecule miRNA inhibitors |
author_facet |
George E. D. Petrescu Alexandru A. Sabo Ligia I. Torsin George A. Calin Mihnea P. Dragomir |
author_sort |
George E. D. Petrescu |
title |
MicroRNA based theranostics for brain cancer: basic principles |
title_short |
MicroRNA based theranostics for brain cancer: basic principles |
title_full |
MicroRNA based theranostics for brain cancer: basic principles |
title_fullStr |
MicroRNA based theranostics for brain cancer: basic principles |
title_full_unstemmed |
MicroRNA based theranostics for brain cancer: basic principles |
title_sort |
microrna based theranostics for brain cancer: basic principles |
publisher |
BMC |
series |
Journal of Experimental & Clinical Cancer Research |
issn |
1756-9966 |
publishDate |
2019-05-01 |
description |
Abstract Background Because of the complexity of the blood-brain barrier (BBB), brain tumors, especially the most common and aggressive primary malignant tumor type arising from the central nervous system (CNS), glioblastoma, remain an essential challenge regarding diagnostic and treatment. There are no approved circulating diagnostic or prognostic biomarkers, nor novel therapies like immune checkpoint inhibitors for glioblastoma, and chemotherapy brings only minimal survival benefits. The development of molecular biology led to the discovery of new potential diagnostic tools and therapeutic targets, offering the premise to detect patients at earlier stages and overcome the current poor prognosis. Main body One potential diagnostic and therapeutic breakthrough might come from microRNAs (miRNAs). It is well-known that miRNAs play a role in the initiation and development of various types of cancer, including glioblastoma. The review aims to answer the following questions concerning the role of RNA theranostics for brain tumors: (1) which miRNAs are the best candidates to become early diagnostic and prognostic circulating biomarkers?; (2) how to deliver the therapeutic agents in the CNS to overcome the BBB?; (3) which are the best methods to restore/inhibit miRNAs? Conclusions Because of the proven roles played by miRNAs in gliomagenesis and of their capacity to pass from the CNS tissue into the blood or cerebrospinal fluid (CSF), we propose miRNAs as ideal diagnostic and prognostic biomarkers. Moreover, recent advances in direct miRNA restoration (miRNA mimics) and miRNA inhibition therapy (antisense oligonucleotides, antagomirs, locked nucleic acid anti-miRNA, small molecule miRNA inhibitors) make miRNAs perfect candidates for entering clinical trials for glioblastoma treatment. |
topic |
microRNA miRNA based drugs Antagomirs Antisense oligonucleotides miRNA masks Small molecule miRNA inhibitors |
url |
http://link.springer.com/article/10.1186/s13046-019-1180-5 |
work_keys_str_mv |
AT georgeedpetrescu micrornabasedtheranosticsforbraincancerbasicprinciples AT alexandruasabo micrornabasedtheranosticsforbraincancerbasicprinciples AT ligiaitorsin micrornabasedtheranosticsforbraincancerbasicprinciples AT georgeacalin micrornabasedtheranosticsforbraincancerbasicprinciples AT mihneapdragomir micrornabasedtheranosticsforbraincancerbasicprinciples |
_version_ |
1724505938070601728 |